|
累計回購金額1.29億港元。 自3月22日以來公司已連續9日進行回購，回購金額達958.07萬港元。全天成交額3755.96萬港元。（數據寶） 先聲藥業回購明細 日期回購股數（萬股）回購最高價（港元）回購最低價（港元）回購金額（萬港元）2024.04.08182.005.3105.200958.072024.04.05179.405.3605.070939.442024.04.03291.505.3105.2001532.802024.04.02178.005.3205.200936.852024.03.28185.005.光光算谷歌seo算谷歌seo代运营4305.280985.942024.03.27183.605.4205.320988.512024.03.2670.005.4805.370379.522024.03.25178.005.4905.360963.122024.03.22185.505.4505.300999.152024.01.19142.105.9805.820835.302024.01.1876.606.1206.040465.712024.01.17162.006.0505.940971.642024.01.1697.006.2406.160601.152024.01.1558.006.2906.210362.532024.01.1266.406.3606.210415.882024.01.0852.006.4006.330331.172024.01.0242.006.5806.510274.97（文章來源：證券時報網）該股當日收盤價5.290港元，4月8日以每股5.200港元至5.310港元的價格回購182.00萬股， 其間該股累計下跌3.64%。先聲藥業 光算谷歌光算谷歌seoseo代运营今年以來該股累計進行17次回購，累計回購金額8683.39萬港元。 |
光算谷歌广告光算谷歌seo公司光算谷歌营销光算谷歌推广光算谷歌推广光算谷歌推广光算谷歌外链光算谷歌seo公司光算谷歌营销光算谷歌外链光算谷歌推广https://synapse.patsnap.com/article/neurocrine-halts-phase-2-neuropsych-med-after-data-validation-failurehttps://synapse.patsnap.com/article/what-is-vinblastine-sulfate-used-forhttps://synapse.patsnap.com/article/novartis-secures-rights-to-kyorins-urticaria-drug-in-830m-dealhttps://synapse.patsnap.com/article/boehringer-ingelheim-expands-ii-portfolio-with-357m-for-cuehttps://synapse.patsnap.com/article/what-are-the-side-effects-of-diatrizoate-sodiumhttps://synapse.patsnap.com/article/how-is-a-biologics-license-application-bla-different-from-an-ndahttps://synapse.patsnap.com/article/ryvu-therapeutics-showcases-rvu120-data-at-2024-european-hematology-association-congresshttps://synapse.patsnap.com/article/what-is-maribavir-used-forhttps://synapse.patsnap.com/drug/b1a1d1cf4f4e43b58b6214b819557b04https://synapse.patsnap.com/drug/2f5616ab06144f9495111cbe04b3c1e7https://synapse.patsnap.com/blog/what-is-bioavailabilityhttps://synapse.patsnap.com/drug/82faf991b8c64cd780ee1de89416f03ehttps://synapse.patsnap.com/drug/576e5ab964b443e08880d06fa4a7d91fhttps://synapse.patsnap.com/article/vironexis-emerges-with-26m-launches-rare-disease-gene-therapieshttps://synapse.patsnap.com/drug/ab5d59ba2c7f401ebac0e1e365ab15a4https://synapse.patsnap.com/drug/3f01cae5863d48e39730f1f0c91c06fdhttps://synapse.patsnap.com/article/calidi-biotherapeutics-updates-on-cld-101-trial-and-highlights-rtnova-cld-201-at-2024-asco-meetinghttps://synapse.patsnap.com/drug/f05d504a34bd4f63be84bc472c5b6d9ehttps://synapse.patsnap.com/drug/2e8d9044f5de46fdbc652414400be2f1https://synapse.patsnap.com/drug/432ebd3223eb4c3a8aca8bab47a1d557https://synapse.patsnap.com/article/what-is-acetylleucine-used-forhttps://synapse.patsnap.com/article/opioid-withdrawal-drug-market-to-grow-at-40-cagr-by-2034https://synapse.patsnap.com/drug/a06afe01f2084bd0879774e07fa7c589https://synapse.patsnap.com/drug/a6b1d5a6cb364cf7bffc8d3629edad83https://synapse.patsnap.com/drug/b736c004e4944879a41f501a0be8574ahttps://synapse.patsnap.com/article/whats-the-latest-update-on-the-ongoing-clinical-trials-related-to-stargardt-diseasehttps://synapse.patsnap.com/article/how-to-adapt-cells-to-serum-free-conditionshttps://synapse.patsnap.com/article/eu-approves-lynozyfic%25E2%2584%25A2-for-relapsedrefractory-multiple-myelomahttps://synapse.patsnap.com/drug/7a4348eb82234a79b3a60d2279be2ea7https://synapse.patsnap.com/drug/c52ac970640b442da58039e4e9e0243b